根据公开信息,翰思艾泰生物医药科技(武汉)股份有限公司(简称“翰思艾泰”)已于2025年6月2日向港交所主板重新递交上市申请,这是继2024年11月首次递表失效后的第二次尝试。一、公司基本背景定位与业务翰思艾泰是一家总部位于湖北武汉的创新生物科技公司,专注于开发癌症及自身免疫疾病的精准治疗药物,聚焦“同类首创”(First-in-Class)和“同类最佳”(Best-in-Class)产品。公司...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.